Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.

Journal Article (Journal Article;Review)

An attractive feature of targeted radionuclide therapy is the ability to select radionuclides and targeting vehicles with characteristics that are best suited for a particular clinical application. One combination that has been receiving increasing attention is the use of monoclonal antibodies (mAbs) specifically reactive to receptors and antigens that are expressed in tumor cells to selectively deliver the alpha-particle-emitting radiohalogen astatine-211 (211At) to malignant cell populations. Promising results have been obtained in preclinical models with multiple 211At-labeled mAbs; however, translation of the concept to the clinic has been slow. Impediments to this process include limited radionuclide availability, the need for suitable radiochemistry methods operant at high activity levels and lack of data concerning the toxicity of alpha-particle emitters in humans. Nonetheless, two clinical trials have been initiated to date with 211At-labeled mAbs, and others are planned for the near future.

Full Text

Duke Authors

Cited Authors

  • Zalutsky, MR; Reardon, DA; Pozzi, OR; Vaidyanathan, G; Bigner, DD

Published Date

  • October 2007

Published In

Volume / Issue

  • 34 / 7

Start / End Page

  • 779 - 785

PubMed ID

  • 17921029

Pubmed Central ID

  • PMC2083568

International Standard Serial Number (ISSN)

  • 0969-8051

Digital Object Identifier (DOI)

  • 10.1016/j.nucmedbio.2007.03.007


  • eng

Conference Location

  • United States